Compare Eli Lilly And Co (LLY) vs D Wave Quantum Inc (QBTS) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

D-Wave Quantum (QBTS) trades at $16.73 with no change on the day, showing bearish technical signals despite a 100% analyst buy rating and $39.86 consensus price target. The company reported Q1 2026 EPS of -$0.05, beating expectations, but maintains deeply negative profitability metrics with a -2,957.23% net income margin. Recent news highlights CEO share sales and sector volatility, while the stock's 29% July decline reflects investor concerns about execution risks in the emerging quantum computing space.

QBTS offers substantial upside potential based on analyst targets but carries high risk due to significant losses, negative cash flow from operations, and speculative technology timeline. The dual-platform quantum strategy provides competitive differentiation, but investors face volatility from pre-commercialization phase challenges and dependence on future funding rounds to sustain operations.